» Articles » PMID: 37643866

Grp78 is Required for Intestinal Kras-dependent Glycolysis Proliferation and Adenomagenesis

Abstract

In development of colorectal cancer, mutations in are often followed by mutations in oncogene The latter changes cellular metabolism and is associated with the Warburg phenomenon. Glucose-regulated protein 78 () is an important regulator of the protein-folding machinery, involved in processing and localization of transmembrane proteins. We hypothesize that targeting in and ()-mutant intestines interferes with the metabolic phenotype imposed by mutations. In mice with intestinal epithelial mutations in , and heterozygosity for ( ) adenoma number and size is decreased compared with mice. Organoids from mice exhibited a glycolysis metabolism which was completely rescued by heterozygosity. Expression and correct localization of glucose transporter GLUT1 was diminished in cells. GLUT1 inhibition restrained the increased growth observed in -mutant organoids, whereas organoids were unaffected. We identify as a critical factor in mutated adenomagenesis. This can be attributed to a critical role for in GLUT1 expression and localization, targeting glycolysis and the Warburg effect.

Citing Articles

Transplantation of gastric epithelial mitochondria into human gastric cancer cells inhibits tumor growth and enhances chemosensitivity by reducing cancer stemness and modulating gastric cancer metabolism.

Tsai H, Tsai K, Wu D, Huang Y, Lin M Stem Cell Res Ther. 2025; 16(1):87.

PMID: 39988680 PMC: 11849191. DOI: 10.1186/s13287-025-04223-7.


Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer.

Wu H, Zhang J, Wang Q, Li Z, Li L, Xie Y Sci Rep. 2025; 15(1):6072.

PMID: 39972191 PMC: 11840008. DOI: 10.1038/s41598-025-90963-8.


The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy.

Ma Q, Zhang W, Wu K, Shi L Mol Cancer. 2025; 24(1):14.

PMID: 39806421 PMC: 11727292. DOI: 10.1186/s12943-024-02218-1.

References
1.
Haber R, Rathan A, Weiser K, Pritsker A, Itzkowitz S, Bodian C . GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1):34-40. DOI: 10.1002/(sici)1097-0142(19980701)83:1<34::aid-cncr5>3.0.co;2-e. View

2.
Ogino S, Nosho K, Kirkner G, Kawasaki T, Meyerhardt J, Loda M . CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2008; 58(1):90-6. PMC: 2679586. DOI: 10.1136/gut.2008.155473. View

3.
Kimmelman A . Metabolic Dependencies in RAS-Driven Cancers. Clin Cancer Res. 2015; 21(8):1828-34. PMC: 4400826. DOI: 10.1158/1078-0432.CCR-14-2425. View

4.
Feng Y, Bommer G, Zhao J, Green M, Sands E, Zhai Y . Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology. 2011; 141(3):1003-1013.e1-10. PMC: 3163826. DOI: 10.1053/j.gastro.2011.05.007. View

5.
Ma Y, Hendershot L . The unfolding tale of the unfolded protein response. Cell. 2002; 107(7):827-30. DOI: 10.1016/s0092-8674(01)00623-7. View